ProBiotix Health Plc (‘ProBiotix’), a life sciences company that develops probiotic formulations to support cardiometabolic health, has entered into a new partnership agreement with SymbioPharm that enables the dietary supplement brand to utilise the CholBiome®CH formulation from ProBiotix to target and reduce cholesterol in its branded range of consumer products.
SymbioPharm, the pioneering German company specialising in microbiome research and evidence-based probiotics, has to date introduced the CholBiome®CH formulation as a premium pharmacy supplement solution across targeted regions. CholBiome®CH is a unique and innovative formulation that offers a European Food Safety Authority (EFSA) health claim, specifically for cholesterol.
Steen Andersen, CEO of ProBiotix Health plc commented: “We are delighted that SymbioPharm, a recognised leader in the probiotic space, has engaged with ProBiotix Health. This collaboration is strategically aligned with our goal of extending the reach of our unique finished product formulations within the DACH region, which includes Germany, Austria, and Switzerland.”
CholBiome®CH contains two active ingredients in a bi-layer tablet – the company’s patented probiotic backed by multiple independent human intervention studies, Lactobacillus plantarum LPLDL®, and Plant Sterols / Stanols (PSS). These combine synergistically to support the reduction of both internal and dietary cholesterol levels via its unique dual action cholesterol reducing formula.
“The award-winning ingredient LPLDL® acts on the internal cholesterol to produce enzymes that break down bile salts,” Andersen continues. “This encourages the liver to remove cholesterol from the blood to replenish required levels and maintain the body’s bile salt pool. Through the secondary action, PSS reduces dietary cholesterol absorption and promotes excretion. Due to the inclusion of PSS, CholBiome®CH can claim to contribute to the maintenance of normal blood cholesterol levels, as backed by EFSA1,” he said.
“Our partnership with SymbioPharm is an important step for us to further expand our business in the consumer health segment, and allow us to reach a broader audience, enhancing market presence and influence.”
Tobias Brodtkorb, CEO of SymbioPharm, commented: “We are very pleased to have entered this agreement with ProBiotix Health. We are a collaborative business and passionate about natural treatments using live bacteria. Our focus is not only on effective therapies but also on the associated diagnostics and scientific research on the microbiome.
“We find our model fits in naturally with ProBiotix and their mission,” he said. “We are delighted to be working closely with them and hope for a strong relationship going forward.”
For more information on ProBiotix Health, visit its website https://dev.accent-adc.co.uk/probiotixhealth
Or for more information on SymbioPharm, visit: https://www.symbiopharm.de/
- EFSA Journal 2010;8(10):1813
